Vivet Therapeutics, a Paris, France-based biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, raised €37.5m in a Series A financing round.
The round was led by Novartis Venture Fund and Columbus Venture Partners, with participation from Roche Venture Fund, HealthCap, Kurma Partners and Ysios Capital.
The company intends to use the funds to advance a diversified pipeline of gene therapy programs targeting rare, inherited metabolic diseases, including Wilson Disease, progressive familial intrahepatic cholestasis type 2 (PFIC2), progressive familial intrahepatic cholestasis type 3 (PFIC3) and citrullinemia type I.
Created in 2016 by Jens Kurth (ex Anokion, Novartis), Gloria Gonzalez Aseguinolaza (CIMA, University of Navarra) and Jean Philippe Combal (ex Gensight Biologics, Sanofi), Vivet Therapeutics Vivet Therapeutics is focused on developing novel gene therapy treatments for rare, inherited metabolic diseases.
The lead program, VTX801, is a novel investigational gene therapy for Wilson disease.
The company is building a diversified gene therapy pipeline based on novel Adeno Associated Virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain; and the Massachusetts Eye and Ear (MEE) of Harvard Medical School, Boston, MA.
Vivet has a wholly-owned subsidiary in Spain.